Our first threesome was such a success, we decided to do it again! Dan and Matt come back on to discuss all of the updates on the BMY CVR since our first post; in particular, we discuss Dan's due diligence that suggests an FDA inspection is on going. 

PS- CVR's are risky and nothing on here is investing advice.

You can find our first threesome here: https://twitter.com/AndrewRangeley/status/1305835912975261697?s=20

My updated take on the CVR here: https://yetanothervalueblog.com/2020/10/bmy-cvr-an-inspection-inflection-bmyrt.html

Twitter handles: 
Matt: Given2Tweet (https://twitter.com/given2tweet)
Dan: Sheep of Wall Street (https://twitter.com/Biohazard3737)

Edwin Dorsey, the founder of the Bear Cave, comes on to talk about short selling, his new newsletter, and his recent report highlighting the red flags at Celsius. Fun fact: Edwin estimates he represents ~1% of the FOIA requests in the U.S.

Edwin's twitter: https://twitter.com/StockJabber
Bear Cave newsletter: https://thebearcave.substack.com/

Shomick Ghosh (aka Minion Capital), a Principal at Boldstart, talks about his experience as a Venture Capitalist and how he balances investing in both public and private companies. Then we dive deep into the investment case for Shopify (SHOP).

Minion Capital twitter: https://twitter.com/MinionCapital
Shomick's twitter: https://twitter.com/shomikghosh21
Boldstart: https://www.boldstart.vc/

Packy McCormick from Not Boring (https://notboring.substack.com/) comes on to talk about the burgeoning Not Boring empire, his experience in angel investing, and his current investment into Opendoor (IPOB).

Bill Brewster discusses his investment into QRTEA. QRTEA is part of the John Malone / Liberty family and owns HSN and QVC. Currently, QRTEA is undergoing some financial engineering which has some people recalling the classic John Malone special situations discussed in You Can Be a Stock Market Genius (https://amzn.to/32ApFqv). Bill talks about why the market might be overlooking QRTEA and why he's excited by the financial engineering.

You can find Bill on twitter @BillBrewsterSCG (https://twitter.com/billbrewsterscg?lang=en). You can also find his write up on QRTEA at https://sullimarcapital.group/2020/09/02/qurate-retail-group/ . I also did a write up on the QRTEA special sit which you can find at: https://yetanothervalueblog.com/2020/09/is-qrtea-a-textbook-malone-special-sit-or-a-classic-value-trap.html .

Matt Turk and Dan Schneeberger do an extremely deep dive into BMYRT. BMYRT is a contingent value right (CVR) established when Bristol-Myers Squibb (BMY) bought Celgene. While CVR's are extremely risky and there is a real chance of this proving worthless, Matt and Dan walk through what a CVR is, why a CVR might be overlooked, and why they think the odds of approval for the drugs underlying BMY's CVR are much higher than the market suggests.

Again, CVRs are risky, and nothing in this podcast is investing advice.

Twitter handles: 
Matt: Given2Tweet (https://twitter.com/given2tweet)
Dan: Sheep of Wall Street (https://twitter.com/Biohazard3737)

Clifford Sosin from CAS Investment Partners discusses his investment track record, his investments in Herbalife (HLF) and Carvana (CVNA), and then dives deep into his current investment into Cardlytics (CDLX).

Marc Rubinstein from Net Interest  (https://netinterest.substack.com/) discusses everything happening in the financial sector: how big banks are taking share during COVID, and financial sectors FANG equivalents.

Dave Waters of Alluvial Capital and OTCAdventures.com comes on the pod to talk about how he got started, his adventures in foreign markets, and his current investment into P10 $PIOE.

Byrne Hobart from The Diff (https://diff.substack.com/) joins us to talk about his recent "The Death of Fang+" series. We dive deep into the question "Which of Amazon / Apple / Microsoft / Google / Netflix / Facebook" is most likely to see serious declines over the next ten years?